EUVIMEDEUVIMED entdecken
Crossref

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups

Gonzalo Borrego-Yaniz, Vera Fuentes-Moreno, Lourdes Ortiz-Fernández, José Hernández-Rodríguez, Sarah L Mackie, Augusto Vaglio, Santos Castañeda, Roser Solans, Jaume Mestre-Torres, Nader Khalidi, Carol A Langford, Steven Ytterberg und 37 weitere

Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · 2241-2252

DOI: 10.1016/j.ard.2026.06.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Gonzalo Borrego-Yaniz und 48 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain. Hauptthemen laut MEDLINE: Giant Cell Arteritis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Institute for Health and Care Research, Leeds Biomedical Research Centre, UK Research and Innovation Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Giant cell arteritis (GCA) is a clinically heterogeneous disease, which complicates both diagnosis and management. This study aimed to identify genetic risk factors associated with GCA clinical manifestations and evaluate their utility for defining clinical phenotypes. METHODS: Genome-wide genotype data from 3498 patients with GCA and 15,550 controls were analysed to investigate the genetic architecture of GCA manifestations. Logistic regression was used to compare patients with and without each manifestation, as well as each subgroup of patients vs controls. Gene annotation was conducted based on functional information using Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS). Latent class analysis (LCA) was applied to evaluate the ability of associated variants to classify patients with GCA into genetic subgroups. RESULTS: We identified 7 human leukocyte antigen (HLA) variants specifically associated with different clinical features. Furthermore, 7 non-HLA associations across 6 clinical manifestations were found. Gene prioritisation highlighted biologically relevant candidate genes for GCA pathogenesis, including IL17A (limb claudication) and IL22RA1 (jaw claudication), both involved in the Th17 pathway, and ATP2A2 (extracranial form), encoding a transporter that promotes aortic aneurysms. Notably, LCA grouped GCA clinical predisposition into 4 classes capturing cranial-predominant, mixed, extracranial, and ischaemic/occlusive patterns, the latter representing a high-risk subgroup for severe ischaemic and ocular complications. CONCLUSIONS: This first genome-wide association study stratified by GCA-specific manifestations deepens our understanding of the genetic basis underlying GCA clinical heterogeneity. Our findings highlight HLA and non-HLA contributors to specific disease phenotypes and support the potential of genetic profiling to guide early diagnosis and personalised management in GCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisHumansGenome-Wide Association StudyFemaleGenetic Predisposition to DiseaseMaleGenetic MarkersAgedPhenotypeInterleukin-17Receptors, InterleukinCase-Control StudiesHLA AntigensGenotypePolymorphism, Single Nucleotide

Substanzen

Genetic MarkersInterleukin-17Receptors, InterleukinHLA AntigensIL23R protein, human

Autor:innen und Institutionen

  • Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain.
  • Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • University of Florence, Department of Biomedical Experimental and Clinical Sciences "Mario Serio", Florence, Italy; Meyer Children's Hospital IRCCS, Nephrology and Dialysis Unit, Florence, Italy.
  • Hospital de la Princesa, IIS-Princesa, Department of Rheumatology, Madrid, Spain.
  • Hospital Vall d'Hebron, Autonomous University of Barcelona, Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Barcelona, Spain.

Förderung

  • National Institute for Health and Care Research
  • Leeds Biomedical Research Centre
  • UK Research and Innovation Medical Research Council
  • Carlos III Health Institute
  • Gobierno de Espana Ministerio de Ciencia e Innovacion

Zitieren

APA

Borrego-Yaniz, G., Fuentes-Moreno, V., Ortiz-Fernández, L., Hernández-Rodríguez, J., Mackie, S. L., Vaglio, A., Castañeda, S., Solans, R., Mestre-Torres, J., Khalidi, N., Langford, C. A., Ytterberg, S., Beretta, L., Govoni, M., Emmi, G., Cimmino, M. A., Witte, T., Neumann, T., Holle, J., …, & Márquez, A. (2026). Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups. Annals of the Rheumatic Diseases, 85(11), 2241-2252. https://doi.org/10.1016/j.ard.2026.06.008

Vancouver

Borrego-Yaniz G, Fuentes-Moreno V, Ortiz-Fernández L, Hernández-Rodríguez J, Mackie SL, Vaglio A, et al. Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups. Annals of the Rheumatic Diseases. 2026;85(11):2241-2252. doi:10.1016/j.ard.2026.06.008

BibTeX
@article{BorregoYaniz2026,
  author = {Borrego-Yaniz, Gonzalo and Fuentes-Moreno, Vera and Ortiz-Fernández, Lourdes and Hernández-Rodríguez, José and Mackie, Sarah L and Vaglio, Augusto and Castañeda, Santos and Solans, Roser and Mestre-Torres, Jaume and Khalidi, Nader and Langford, Carol A and Ytterberg, Steven and Beretta, Lorenzo and Govoni, Marcello and Emmi, Giacomo and Cimmino, Marco A and Witte, Torsten and Neumann, Thomas and Holle, Julia and Schönau, Verena and Pugnet, Gregory and Papo, Thomas and Haroche, Julien and Mahr, Alfred and Mouthon, Luc and Molberg, Øyvind and Diamantopoulos, Andreas P and Voskuyl, Alexandre and Daikeler, Thomas and Berger, Christoph T and Molloy, Eamonn S and van Sleen, Yannick and Sorensen, Louise and Luqmani, Raashid and Spanish GCA Group, Spanish GCA Group and UK GCA Consortium, UK GCA Consortium and Vasculitis Clinical Research Consortium, Vasculitis Clinical Research Consortium and Ortego-Centeno, Norberto and Brouwer, Elisabeth and Lamprecht, Peter and Klapa, Sebastian and Salvarani, Carlo and Merkel, Peter A and Cid, María C and Iles, Mark M and González-Gay, Miguel A and Morgan, Ann W and Martin, Javier and Márquez, Ana},
  title = {Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {11},
  pages = {2241--2252},
  doi = {10.1016/j.ard.2026.06.008}
}
Kostenlos starten →